Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Perioperative CapeOx for advanced gastric cancer with extensive lymph node metastases
jRCTs051180186Phase 2Completed
- Sponsor
- Yakult Honsha
- Start
- Feb 2018
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of capecitabine and oxaliplatin in gastric cancer (GC), sponsored by Yakult Honsha. Primary endpoint: Response rate. Started Feb 2018; status: completed.
02
Drugs
capecitabineoxaliplatin
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on jRCTs051180186.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs051180186.